AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Chinese fund: “The Chinese government has imposed a ban on any new investment in Israel”
2
Israeli defense firms target Asia as Singapore Airshow opens amid regional arms race
3
Medtronic to acquire Israeli AI cardiology firm CathWorks for $585 million, deal could reach $1 billion
4
After $400M cyber exit, ex-IntSights CEO raises $11M to build AI app for personalized sports highlights
5
“SaaS is dying as a business category”
More news

Teva

20 stories about Teva
אתר טבע כפר סבא

Fitch Downgrades Teva, Keeps Outlook at Negative

10.06.19|Hezi Sternlicht
Fitch pins the downgrade on the drugmaker's slow revenue growth, persisting cost challenges and downward pressure on generic drug prices, and the company's legal trouble in the U.S.
מטה חברת טבע תרופות

Derivative Suit Sheds Light on Teva’s Disastrous Rimsa Acquisition

28.05.19|Hezi Sternlicht
Teva acquired Mexican drugmaker Rimsa in 2016, but an anonymous email sent a week after the deal’s completion led Teva to launch an internal investigation—and sue the sellers for fraud
מטה חברת טבע תרופות

Teva Reaches $85 Million Settlement in Oklahoma Opioid Damages Suit

27.05.19|Hezi Sternlicht
Teva is one of several opioid manufacturers being sued in the U.S. by different states and private entities for its alleged role in the nation's opioid addiction crisis
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Legal Troubles Could Weigh Down Teva’s Ability to Carry its Debt Covenants

16.05.19|Uri Tal-Tenne
On one hand, Teva is facing lawsuits that could end up costing it hundreds of millions of dollars; on the other hand, new profitable drugs and a cost-cutting reorganization program. Is it enough to keep its head above water?
מטה חברת טבע תרופות

This Is how Teva and 19 of its Rivals Fixed U.S. Drug Prices

15.05.19|Hezi Sternlicht, Ran Abramson, and Tomer Ganon
A 524-page civil lawsuit filed Friday in the U.S. alleges that 20 generic drugmakers colluded to influence drug prices, with executives meeting regularly to set prices and split the market
הבורסה לניירות ערך רחוב אחוזת בית תל אביב

Teva no Longer Largest Company on TASE After U.S. Legal Troubles Sink Stock

13.05.19|Lilach Baumer
International Flavors & Fragrances (IFF), which listed on the Tel Aviv exchange in October following its acquisition of Israel-based Frutarom, has now surpassed the Israeli drugmaker
מטה חברת טבע תרופות

Teva’s Shady Legal Past Still Weighs on the Debt-Laden Pharma Company

12.05.19|Hezi Sternlicht
On Friday, 43 states joined Connecticut in filing a lawsuit against senior Teva executives and against over a dozen former and current senior executives at leading generic drug companies, alleging all were involved in a drug price-fixing conspiracy
כנס קנאביס פרי דוידסון סאייקי מדיקל

For Medical Cannabis Users, the Biggest Problem Is a Consistent Dose, Says Syqe Medical CEO

07.05.19|Orna Yefet
Perry Davidson, founder and CEO of cannabis inhaler company Syqe Medical, spoke Monday at Calcalist's cannabis conference in Tel Aviv
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva’s Copaxone Successors Are Still Far From Success

05.05.19|Hezi Sternlicht
Teva’s first quarter report for 2019, published Thursday, shows that while the drugmaker is progressing with its financial rehabilitation program, its net debt to EBITDA ratio is leaving the company in dangerous waters
קרית שמונה קריית שמונה

Teva Completes $47.5 Million Sale of Northern Israeli Plant to Private Equity Fund FIMI

02.05.19|Hezi Sternlicht
Teva is selling the plant following its 2017 plan to ameliorate its crippling debt by divesting non-core businesses and closing or selling many of its manufacturing plants
אתר טבע כפר סבא

Teva Discontinues Development of Cluster Headache Drug

24.04.19|Tzally Greenberg
Under Teva’s brand name Ajovy, fremanezumab has already been approved in the U.S. and Europe as a preventative migraine treatment
מטה טבע פתח תקווה

FDA Approves Teva’s Generic Nasal Spray for Opioid Overdose

21.04.19|Lilach Baumer
Commonly known as Narcan, the spray is considered a life-saving medication, and Teva’s drug is the first generic product approved that does not require medical training to use
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Execs Topped TASE's High Earners List for 2018

18.04.19|Gil Kalian
With nearly $34 million added to the bank, Teva’s CEO Kåre Schultz was the highest earning executive on the Tel Aviv Stock Exchange last year
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Market Indifferent to European Approval of Teva's Migraine Drug

02.04.19|Lilach Baumer
Teva's injection, one of three similar migraine drugs already approved in the U.S., is the third to receive European approval after Amgen Inc. and Novartis AG and Eli Lilly
חברת ה תרופות טבע Teva

Teva Makes Headway in European Copaxone Patent Case

01.04.19|Lilach Baumer
Generic 40 mg versions of the drugmaker's blockbuster drug for multiple sclerosis have been available in Europe since late 2017, but Teva is now making strides in court
מפעל טבע הר חוצבים ירושלים

Bidder Contests Teva Sale of Jerusalem Facility

31.03.19|Amitai Gazit and Lilach Baumer
Earlier this month, Teva agreed to sell the land tenure rights of its two Jerusalem factories, set to close by the end of 2019, for a combined $77 million
מטה טבע פתח תקווה

Teva Settles Patent Litigation Case for Blood Sugar Stabilizer With Novo Nordisk

24.03.19|CTech
Under the settlement agreement, Teva will be able to sell a generic version of the drug as of 2023
מפעל חברת טבע הר חוצבים ירושלים

Teva Selling Jerusalem Land Tenure Rights Ahead of Factory Closures

20.03.19|Golan Hazani
Teva currently has two manufacturing plants in Jerusalem, both slated for closure by the end of 2019
נסיעת בכורה של רכבת מהירה מ ירושלים ל תל אביב

Copaxone-Competitor Developer Mapi Pharma Gets Funding for Jerusalem Plant

19.03.19|Lilach Baumer
The clinical-stage company develops more efficient versions of existing successful drugs, including a long-acting version of Teva's multiple sclerosis cash cow
דוד לוסטיג סמנכ"ל בכיר מנהל התפעול טבע ישראל

Senior Vice President David Lustig Leaving Teva After 25 Years

19.03.19|Tzally Greenberg
Lustig will be replaced by Miran Denac, currently senior vice president and cluster manager for central and Western Europe operations
Previous ArticlesMore Articles